Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LIPO-Liposome -- Ignore unavailable to you. Want to Upgrade?

To: Cheeseburger who wrote (781)	8/30/1999 3:21:00 PM
From: KM	Respond to of 900

First day that I can remember that the money flow has been positive and there have been buy indications in IWatch. I bought a bunch at 20.5 Just saw a 50k buy at 20 3/4 But AVLN is still hanging around, shorting.

To: Cheeseburger who wrote (781)	8/30/1999 3:35:00 PM
From: G-MAN	Read Replies (2) \| Respond to of 900

I am wondering if the market is pushing this stock back to a price that would fairly represent the value of this company with the approval of Evacet. I read a H&Q report issued back in July and they mentioned that the current price of $18 (& some change) represented the fair value of LIPO with the Evacet approval. Without Evacet, they mentioned that $12 was a fair value. They also mentioned that they reviewed the data provided by the company and see a strong case for recommendation. It is interesting that they see a positive light and this Avalon Group, that has been shorting the stock, sees it the other way. Given this estimate, I am now wondering if we will see LIPO pull back to $16 to 18. With a positive recommendation, we might see the mid 20's for a brief moment. The price action of this stock is not acting as if: A)a positive recommendation will be received, or B)it is fairly valued as of this moment in time. My guess is that the stock price is a little overpriced. For those of us who bought into the stock in the 20's expecting a price of $30 soon, we might be disappointed for the time being. For those who bought in the low teens, I see relatively low risk. Are there any thoughts?